Login to Your Account

Week in Review

Monday, November 28, 2011


ChanRx Corp. raised $5.5 million in a Series A round for its atrial fibrillation drug.

Coronado Biosciences Inc.'s stock debuted on the Over The Counter Bulletin Board at $11 after taking a Form 10 path to get public.

Portola Pharmaceuticals Inc. raised $89 million in a Series D financing.


Excaliard Pharmaceuticals Inc. is being acquired by Pfizer Inc. (no terms).

Gilead Sciences Inc.

To continue reading subscribe now to BioWorld Insight

Learn More about BioWorld Insight

Already a subscriber? Sign In or Buy now to activate your subscription